|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
10/19/2005 5:13:03 PM
SAN DIEGO--(BUSINESS WIRE)--March 16, 2005--Synbiotics Corporation (Pink Sheets:SBIO) announced today that it has entered into a Distribution Agreement with Viral Antigens, Inc. (VAI), a wholly-owned subsidiary of Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) for the distribution of VAI's veterinary products through Synbiotics' global sales, marketing and distribution channels. Synbiotics currently develops, manufactures, and markets veterinary diagnostic products for the global animal health market and is seeking to broaden its product portfolio. Synbiotics will immediately begin marketing the Pseudorabies Virus Antibody test kit and the Autolex(R) Anti-PRV Screen globally. VAI will continue to supply PRV test kits directly to Japan.
Pseudorabies Virus (PRV) is a contagious swine disease that causes reproductive problems, including abortion, stillbirths and even occasional death losses in breeding and finishing hogs. PRV has been one of the most costly of all swine diseases to the nation's pork producers. At its peak in the 1990's, the cost to pork producers alone was estimated to be $30 million annually represented in vaccination, testing, and animal loss costs. Over the past decade, a national control and eradication program for PRV was implemented to eliminate the presence of PRV in the swine population. Today, tight biosecurity, vaccination, testing, and good disease management practices are utilized to control the impact of PRV.
|
|
|
|
|
|
|
|
|
|
|